An investigational oral Janus kinase (JAK) inhibitor failed to meet most primary endpoints in a phase III trial of patients ...

The researchers found nearly half (47%) of the posts focused on efficacy, while 16% discussed adverse effects such as acne, ...

Deuruxolitinib showed significant efficacy and safety in hair regrowth stimulation among adult patients with alopecia areata, ...

Fedratinib can reduce symptoms and spleen volume in patients with myelodysplastic syndrome (MDS) or myeloproliferative neoplasms (MPNs), according to research presented at the ASH Annual Meeting 2024.

Alumis is advancing ESK-001 for plaque psoriasis with phase 3 data expected in 2026. Read why ALMS stock is compelling yet ...

Filgotinib, a JAK1 preferential inhibitor, shows promise as an effective and well-tolerated maintenance therapy for Crohn's ...

The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and ...

Geron (GERN) announced results from an oral presentation at the 66th American Society of Hematology, or ASH, annual meeting, reporting Phase 1 ...

Jacobio Pharma (1167.HK), a clinical-stage oncology company dedicated to developing therapies toward undruggable targets, today presented preliminary Phase I data of BET inhibitor JAB-8263 to treat ...